EUVIMEDEUVIMED entdecken
Crossref

Pentatricopeptide repeat protein targeting CUG repeat RNA ameliorates RNA toxicity in a myotonic dystrophy type 1 mouse model

Takayoshi Imai iD, Maiko Miyai, Joe Nemoto iD, Takayuki Tamai, Masaru Ohta iD, Yusuke Yagi iD, Osamu Nakanishi iD, Hideki Mochizuki, Masayuki Nakamori iD

Science Translational Medicine · 16.04.2025 · 17 (794)

DOI: 10.1126/scitranslmed.adq2005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 16.04.2025. Verfasst von Takayoshi Imai und 8 weiteren Autor:innen. Beteiligte Einrichtung: EditForce Inc., Fukuoka 819-0395, Japan. Hauptthemen laut MEDLINE: Myotonic Dystrophy, RNA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder caused by the expansion of a CTG-triplet repeat in the 3′ untranslated region of the dystrophia myotonica protein kinase ( DMPK ) gene. It results in the transcription of toxic RNAs that contain expanded CUG repeats (CUG exp ). Splicing factors, such as muscleblind-like 1 (MBNL1), are sequestered by CUG exp , thereby disrupting the normal splicing program that is essential for various cellular functions. Pentatricopeptide repeat (PPR) proteins, originally found in plants, regulate RNA in organelles by binding in a sequence-specific manner. Here, we designed PPR proteins that specifically bind to the hexamer of CUG repeat RNAs (CUG-PPRs) and showed that CUG-PPR1 could ameliorate RNA toxicity induced by CUG exp in cell models of DM1. A single systemic recombinant adeno-associated virus (AAV9) vector–mediated gene delivery of CUG-PPR1 demonstrated long-term therapeutic effects on myotonia and restored splicing activity in a mouse model of DM1. These results highlight the potential of PPR molecules to target pathogenic RNA sequences in DM1 and potentially other RNA-mediated disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyRNAAnimalsDisease Models, AnimalRNA-Binding ProteinsMiceHumansRNA SplicingMyotonin-Protein KinaseDependovirusGenetic TherapyTrinucleotide Repeat Expansion

Substanzen

RNA-Binding ProteinsRNAMyotonin-Protein Kinase

Autor:innen und Institutionen

  • EditForce Inc., Fukuoka 819-0395, Japan.
  • Department of Neurology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
  • Department of Neurology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan.
  • Faculty of Agriculture, Kyushu University, Fukuoka 819-0395, Japan.

ORCID-Profile: Takayoshi Imai, Joe Nemoto, Masaru Ohta, Yusuke Yagi, Osamu Nakanishi, Masayuki Nakamori

Zitieren

APA

Imai, T., Miyai, M., Nemoto, J., Tamai, T., Ohta, M., Yagi, Y., Nakanishi, O., Mochizuki, H., & Nakamori, M. (2025). Pentatricopeptide repeat protein targeting CUG repeat RNA ameliorates RNA toxicity in a myotonic dystrophy type 1 mouse model. Science Translational Medicine, 17(794). https://doi.org/10.1126/scitranslmed.adq2005

Vancouver

Imai T, Miyai M, Nemoto J, Tamai T, Ohta M, Yagi Y, et al. Pentatricopeptide repeat protein targeting CUG repeat RNA ameliorates RNA toxicity in a myotonic dystrophy type 1 mouse model. Science Translational Medicine. 2025;17(794). doi:10.1126/scitranslmed.adq2005

BibTeX
@article{Imai2025,
  author = {Imai, Takayoshi and Miyai, Maiko and Nemoto, Joe and Tamai, Takayuki and Ohta, Masaru and Yagi, Yusuke and Nakanishi, Osamu and Mochizuki, Hideki and Nakamori, Masayuki},
  title = {Pentatricopeptide repeat protein targeting CUG repeat RNA ameliorates RNA toxicity in a myotonic dystrophy type 1 mouse model},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {794},
  doi = {10.1126/scitranslmed.adq2005}
}
Kostenlos starten →